GLP-1 medications have changed the conversation around weight loss, insulin resistance, and metabolic disease. For many people, they can be clinically useful tools. Appetite comes down, food noise settles, blood sugar control improves, and weight loss can occur in a way that previously felt impossible. That part of the story is real. But the other part of the story, the one that deserves more critical discussion, is what happens when we achieve those outcomes by slowing the upper gut. Semaglutide’s prescribing information explicitly notes delayed gastric emptying as part of its pharmacology, and recent reviews have explored how GLP-1 receptor agonists influence gastric motility and gastroparesis-like symptoms.  

That does not mean every person on a GLP-1 will develop a gut disorder, and it would be too simplistic, and frankly inaccurate, to say these drugs “cause SIBO” across the board. But it is clinically reasonable to ask whether a therapy that slows gastric emptying and can alter downstream transit may, in some people, create a more permissive environment for bacterial overgrowth, especially when other risk factors are already present. Established SIBO guidelines already recognize motility disorders and prior abdominal surgery as relevant risk settings for testing symptomatic patients. In other words, the mechanism we are worried about is not invented out of thin air; it fits within what gastroenterology already understands about how SIBO develops.  

To understand why this matters, it helps to define SIBO properly. SIBO, or small intestinal bacterial overgrowth, occurs when bacteria that normally belong in much higher numbers in the colon are present in excessive amounts in the small intestine. The small intestine is built primarily for digestion and nutrient absorption, not heavy fermentation. When microbes begin fermenting food there, people can experience bloating, abdominal discomfort, excess gas, reflux-like pressure, constipation or diarrhea, and progressively more food reactivity. Longer term, SIBO can also impair absorption and contribute to deficiencies in nutrients such as vitamin B12 and iron, while fat malabsorption can disturb fat-soluble vitamin status.  

The critical point is that SIBO is usually not just a “bacteria problem.” It is often a physiology problem first. Bacteria overgrow when the terrain allows it. That terrain can be shaped by reduced stomach acid, impaired immune defenses, altered anatomy, poor migrating motor complex activity, or slower small-bowel transit. The ACG guideline specifically recommends breath testing in symptomatic patients with suspected motility disorders and in symptomatic patients with prior luminal abdominal surgery, which tells us something important: slowed movement and altered anatomy are not side notes in SIBO, they are central risk concepts.  

This is where GLP-1 medications deserve a more nuanced discussion. Their metabolic benefits are clear, but one of the ways they help is by slowing early postprandial gastric emptying, which increases satiety and reduces the speed at which nutrients move onward. In some people, that may simply mean eating less and feeling fuller for longer with no major gut consequences. In others, especially those with pre-existing constipation, low stomach acid, vagal dysfunction, diabetes-related dysmotility, prior abdominal surgery, PPI use, or a history suggestive of SIBO, the same mechanism may become a problem. It is not just the stomach that matters here. If upstream slowing contributes to downstream stagnation, then the small intestine can become a more favorable place for fermentation and overgrowth. That is the biological plausibility behind the concern.  

What is especially interesting is that the direct evidence is now beginning to emerge, but it is still early enough that we should be careful not to overstate it. A 2025 study reported an association between GLP-1 receptor agonist use and both SIBO and intestinal methanogen overgrowth, and another 2025 analysis suggested increased short-term SIBO risk with GLP-1 or dual GLP-1/GIP therapy. Those findings are clinically relevant, but they are not yet the same thing as definitive proof that GLP-1 therapy independently causes SIBO in the general population. They do, however, strengthen the argument that if a patient develops persistent bloating, constipation, upper abdominal fullness, or food intolerance after starting one of these agents, we should not dismiss it as a trivial side effect or automatically assume it is “just normal adjustment.”  

There is another layer here that often gets missed in popular conversation: sometimes what is labelled as “SIBO from GLP-1s” may actually be a broader motility picture. Some patients may have delayed gastric emptying, some may have constipation-dominant intestinal slowing, some may have methanogen overgrowth rather than classic hydrogen-dominant SIBO, and some may simply have medication-induced symptoms that mimic these patterns. Clinically, that matters because the treatment approach is not identical. The more thoughtful approach is not to force every patient into the same diagnosis, but to ask better questions. Is this delayed gastric emptying? Is this small bowel stasis? Is this constipation with methanogen overgrowth? Is this poor meal patterning layered onto already-fragile digestion? Critical thinking here prevents overdiagnosis just as much as it prevents under-recognition.  

The gastric sleeve conversation sits in a similar, but not identical, space. Sleeve gastrectomy does not work via the same pharmacologic mechanism as a GLP-1 agonist, but it absolutely changes digestive physiology. The stomach is physically altered, meal volume is reduced, food tolerance changes, and downstream digestive dynamics can shift. Long-term bariatric literature consistently raises concern about nutritional deficiencies, altered anatomy, and microbiome-related complications, including SIBO in some patients. Bariatric guidance and reviews highlight ongoing risks for deficiencies in iron, vitamin B12, vitamin D, calcium, and protein status after surgery, and altered GI anatomy is already recognized as a setting where SIBO should be considered when symptoms fit.  

This matters because when people talk about either GLP-1s or gastric sleeve surgery, the discussion often stays very weight-centric. Did the patient lose weight? Did their glucose improve? Did appetite come down? Those are important outcomes, but they are not the whole picture. A person can lose weight and still move into a physiologically fragile state if they also develop chronic constipation, worsening reflux, bloating after meals, micronutrient depletion, muscle loss, or an increasingly restricted food intake because eating has become uncomfortable. Weight loss is not always the same as health restoration. That is not an argument against these interventions; it is an argument for monitoring them with more maturity.  

The long-term implications of untreated SIBO are also bigger than many people realize. Yes, there are the obvious symptoms like bloating and bowel changes, but the downstream effects can be more disruptive than that. Chronic overgrowth can impair nutrient absorption, raise inflammatory burden, worsen fatigue, amplify food intolerance, and make body composition change harder to sustain because the person becomes less metabolically resilient. If you are undernourished, inflamed, constipated, reacting to more foods, and struggling with poor energy, you are not in a good position to maintain lean mass, train well, regulate appetite normally, or support healthy thyroid and sex hormone signaling. In that sense, unresolved SIBO can quietly work against long-term fat loss maintenance even when it began in the context of a weight-loss intervention.  

This is exactly why a functional medicine lens is useful here. Not because it rejects medications or surgery, but because it asks what the intervention is doing to the rest of the system. Is motility slowing too much? Is the person eating so little protein and fiber that they are losing resilience? Are they constipated and increasingly reactive to food? Are they developing iron or B12 deficiency? Are they relying on the weight-loss outcome while ignoring the digestive cost? A systems-based model does not demonize tools. It simply refuses to look at one benefit in isolation from the wider physiology.  

So the most balanced clinical conclusion is that GLP-1s are not inherently “bad for the gut,” and gastric sleeve surgery is not automatically a sentence to dysbiosis. But both can alter digestive physiology in ways that may increase risk in susceptible people. The current evidence most strongly supports concern around delayed gastric emptying, altered transit, prior surgery, nutritional compromise, and symptomatic patients who fit known SIBO risk profiles. The SIBO link with GLP-1 therapy is plausible and now supported by emerging data, but it should still be framed as an evolving area rather than a settled universal truth. That balance matters, because good clinical thinking is not about being dramatic. It is about being precise.

References 

American College of Gastroenterology. (2020). ACG clinical guideline: Small intestinal bacterial overgrowth. https://www.spg.pt/wp-content/uploads/2023/03/ACG-Clinical-Guideline-Small-Intestinal-Bacterial-Overgrowth.pdf 

U.S. Food and Drug Administration. (2025). Wegovy (semaglutide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf 

Mancini, A., Imperlini, E., Nigro, E., Montagnese, C., Daniele, A., & Orrù, S. (2024). Metabolic effects and mechanisms of GLP-1 receptor agonists: A comprehensive review. International Journal of Molecular Sciences, 25(1). https://pmc.ncbi.nlm.nih.gov/articles/PMC11620716/ 

Smith, J., & Patel, R. (2025). Association between GLP-1 receptor agonists and small intestinal bacterial overgrowth. Journal of Translational Gastroenterology. https://journals.sagepub.com/doi/10.1177/26345161251353437 

Busetto, L., Dicker, D., Azran, C., Batterham, R. L., Farpour-Lambert, N., Fried, M., Hjelmesæth, J., Kinzl, J., Leitner, D. R., Makaronidis, J., Schindler, K., Toplak, H., Widhalm, K., Yumuk, V., & Frühbeck, G. (2024). Practical recommendations of the obesity management task force of the European Association for the Study of Obesity for the post-bariatric surgery medical management. Journal of Personalized Medicine, 14(6). https://www.mdpi.com/2075-4426/14/6/650